CD40 Ligand Expressing MSLN-CAR T Cell Therapy in MSLN Positive Advanced/Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
In preclinical study, investigators have demonstrated that the newly developed CD40 ligand
expressing MSLN-CAR T cells possess more powerful antitumor activity than previously reported
CAR-MSLN T cells in animal models. In this clinical trial, at least 9 eligible patients in
dose escalation period will be enrolled to receive 3 doses of CD40 ligand expressing MSLN-CAR
cell therapy according to the "3+3" principle. In dose expansion period, additional 10 to 21
patients will be enrolled to receive CD40 ligand expressing MSLN-CAR T cell therapy at dose
of RP2D.